METHODS AND COMPOSITIONS FOR ASTHMA TREATMENT USING ANTIBODIES AGAINST IL-13 Russian patent published in 2017 - IPC A61K39/395 

FIELD: pharmacology.

SUBSTANCE: method includes intravenous administration to an individual an antibody against IL-13 or its antigen-binding portion in a dose of about 0.3 mg/kg. Antibody against IL-13 or its antigen-binding portion contain a variable region of heavy chain SEQ ID NO:2 and variable region of light chain SEQ ID NO:3, where at least one pharmacokinetic characteristic, isolated from the group consisting of: (a) the maximum serum concentration (Smax), equal to about 55 to about 90 μg/ml, and (b) the area under the concentration-time curve for serum (AUC) which is equal to approximately 20000 up to approximately 34000 mcg/ml, is reached after administration of antibody or its antigen-binding part to a specified individual. The group of inventions also refers to variants of a method of treating bronchial asthma from mild to moderate form.

EFFECT: optimum dosage and the schedule for administration of the above antibody to produce certain pharmacokinetic characteristics.

9 cl, 4 ex, 7 tbl, 12 dwg